Use of Alkasite for Postpulpotomy Restoration (Cention-Forte)
Clinical Evaluation of Alkasite Composite as a Final Restoration for Pulpotomized Primary Molars.
The aim of this study will be directed to:
Evaluate the clinical performance of alkasite composite as a final restoration for pulpotomized primary molars.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tanta, Egypt
- The clinical study was carried out at the clinic of Pediatric and Preventive Dentistry Department, Faculty of dentistry, Tanta university.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Deep carious vital primary molars at site 1, 2, and size 3 according to the SI/STA classification of caries.
- Healthy children free from systemic diseases.
- Cooperative patient: Frankel rating 3,4.
Radiographically:
- Deep caries approximating the pulp.
- Roots with no more than one-third physiologic resorption.
- Normal lamina dura and periodontal ligament space.
Exclusion Criteria:
- Patients with bruxism.
- Clinical signs or symptoms of irreversible pulpitis or pulp degeneration.
- Parents refuse treatment.
Radiographically:
- Furcation involvement.
- periapical lesion.
- Pathologic resorption (internal or external).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group I: Study group :Alkasite( cention forte )
25 primary molars were restored with an Alkasite composite Cention-forte after Formocresol pulpotomy.
|
25 primary molars were restored with an Alkasite composite Cention-forte after Formocresol pulpotomy.
Other Names:
|
|
Active Comparator: Group II :Control group: Tetric N-Ceram
25 primary molars were restored with Tetric® N-Ceram bulk-fill composite after Formocresol pulpotomy.
|
5 primary molars were restored with Tetric® N-Ceram bulk-fill composite after Formocresol pulpotomy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical evaluation of the final restoration according to USPHS Criteria
Time Frame: at 3, 6, and 9 months
|
Clinical evaluation of the final restoration is done according to the modified united states public health service USPHS Criteria for direct clinical evaluation of restoration
|
at 3, 6, and 9 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Faten Abu Taleb, faculty of dentistry Tanta university
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- #P-PED-6-24-2204
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.